Tosca Holtrop

Dr. Tosca Holtrop

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in Viruses
Verified
Journal Article
Open access
PDF file
SKSteffen Krohn
Steffen Krohn
THTosca Holtrop
Tosca Holtrop
ABArianne M. Brandsma
Arianne M. Brandsma
PMPetra Moerer
Petra Moerer
MNMaaike Nederend
Maaike Nederend
Matthias PeippMatthias Peipp
Matthias Peipp
Antibodies that specifically bind to individual human fragment crystallizable γ receptors (FcγRs) are of interest as research tools in studying immune cell functions, as well as components in bispecific antibodies for immune cell engagement in cancer therapy. Monoclonal antibodies for human low-affinity FcγRs have been successfully generated by hybridoma technology and are widely used in pre-clinical research. However, the generation of monoclonal antibodies by hybridoma technology that specifically bind to the high-affinity receptor FcγRI is challenging. Monomeric mouse IgG2a, IgG2b, and IgG3 bind human FcγRI with high affinity via the Fc part, leading to an Fc-mediated rather than a fragment for antigen binding (Fab)-mediated selection of monoclonal antibodies. Blocking the Fc-binding site of FcγRI with an excess of human IgG or Fc during screening decreases the risk of Fc-mediated interactions but can also block the potential epitopes of new antibody candidates. Therefore, we replaced hybridoma technology with phage display of a single-chain fragment variable (scFv) antibody library that was generated from mice immunized with FcγRI-positive cells and screened it with a cellular panning approach assisted by next-generation sequencing (NGS). Seven new FcγRI-specific antibody sequences were selected with this methodology, which were produced as Fc-silent antibodies showing FcγRI-restricted specificity.

28 October 2025 in mAbs
Verified
Journal Article
Open access
THTosca Holtrop
Tosca Holtrop
EPElsemieke M. Passchier
Elsemieke M. Passchier
SOSophie O’tOole
Sophie O’tOole
WKW. Joost Kraan
W. Joost Kraan
KBKevin Budding
Kevin Budding
JLJeanette H.W. Leusen
Jeanette H.W. Leusen
FcγRI (CD64) is the only Fcγ receptor capable of high-affinity binding to monomeric IgG and found on monocytes, macrophages, eosinophils, neutrophils, and dendritic cells. FcγRI contains three C2-type immunoglobulin (Ig) extracellular domains (EC1-3), while all other Fcγ receptors contain only two EC domains. For detection, several FcγRI-specific antibodies have been described. The most frequently used commercial antibody is clone 10.1, which is proposed to bind the membrane proximal domain EC3. Other anti-FcγRI antibodies include 197, m22/H22 and C09, but their exact binding domains are unknown. A clear overview of binding affinities and functional properties for all these antibodies is lacking. We identified the binding characteristics and functional properties of five anti-human FcγRI antibodies via flow cytometry, LigandTracer and luminol-based chemiluminescence assays. Subsequently we verified their domain specificity using chimeric FcγRI receptors in which EC1-EC3 were swapped with their murine counterparts. Surprisingly, all anti-FcγRI antibodies bind to EC1 of FcγRI, while swapping of EC3 had no effect on binding. Affinity measurements showed similar affinities amongst all antibodies, despite varying association and dissociation rates, except for clone 10.1, which has a > 100-fold lower affinity. These findings strengthen the notion that EC1 is critical for receptor folding, structural integrity, and high-affinity IgG recognition, reinforcing its importance in FcγRI and its potential implications for targeted therapies. By redefining the binding domain of anti-FcγRI antibodies, this study provides a more accurate framework for utilizing FcγRI as a biomarker and therapeutic target in immunotherapy and diagnostics.

15 September 2026 in Cells
Verified
Journal Article
Open access
PDF file
THTosca Holtrop
Tosca Holtrop
IPIda van der Peet
Ida van der Peet
IHIlona S. T. Hendriks
Ilona S. T. Hendriks
TKTineke Kardol-Hoefnagel
Tineke Kardol-Hoefnagel
RSRobin B. Schol
Robin B. Schol
MTMaria Tsioumpekou
Maria Tsioumpekou
The acidic tumor microenvironment (pH 6.3–7.1) influences immune cell function, yet its impact on antibody-mediated killing remains poorly understood. While natural killer (NK) cells lose their spontaneous tumor-killing ability in acidic conditions, the effect on IgG-mediated killing is unexplored. Neutrophils, key effector cells in IgA immunotherapy, respond to pH changes by delayed apoptosis and show impaired bacterial killing. In this study, we investigated how extracellular acidity affects immune cell function and modulates antibody-dependent cytotoxicity by neutrophils and peripheral blood mononuclear cells (PBMCs) across multiple in vitro tumor models. Contrary to expectations, acidity significantly enhanced both IgG- and IgA-mediated tumor cell killing by neutrophils, while IgG-mediated antibody-dependent cellular cytotoxicity (ADCC) by PBMCs had a varying impact. This increased neutrophil activity was accompanied by elevated IgA-driven trogocytosis, while protumor reactive oxygen species production and neutrophil extracellular trap (NET) formation were suppressed. Cytokine profiling and Western blot analysis revealed increased Leukotriene B4 (LTB4) secretion and extracellular signal-regulated kinase (Erk) signaling, supporting enhanced neutrophil recruitment and activation in acidic conditions. Our findings reveal that, unlike other immune subsets, neutrophils maintain or even boost antibody-mediated effector functions in the acidic tumor microenvironment, providing new insight into neutrophil biology in tumors and supporting further investigation of neutrophil-targeted antibody immunotherapies.